Background and Goal: The HOMER study was launched to determine the most effective setting for starting buprenorphine treatment for opioid use disorder. The study faced challenges including shifts in health care delivery, changes in patient preferences, and the emergence of telehealth. The goal was to adapt the study to these circumstances while maintaining its focus on patient-centered care and effective treatment outcomes.
Key Insights: The HOMER study had to quickly adapt to challenges brought on by the COVID-19 pandemic. With community input, the study design evolved to include a third arm, telehealth, in response to the rapid shift in health care delivery methods. As the study progressed, it became clear that both patients and clinicians had strong preferences for specific induction methods. This led to shifting from a purely randomized approach to a comprehensive cohort design, allowing the study to accommodate patients who preferred not to be randomized. Despite numerous challenges, as of January 2024, HOMER has enrolled nearly 300 study participants, and practices are still participating.
Why It Matters: The experiences and adaptations of the HOMER study show how research can remain resilient and responsive in the face of unforeseen challenges and keep studies relevant and patient-centered.
The Odyssey of HOMER: Comparative Effectiveness Research on Medication for Opioid Use Disorder During the COVID-19 Pandemic
Linda Zittleman, MSPH, et al
University of Colorado Department of Family Medicine, Aurora, Colorado
PRE-EMBARGO LINK (Link expires at 5 p.m. September 23rd, 2024)
